Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Craig Lipset, head of clinical innovation at Pfizer Inc., will join advocates of patient data accessibility to highlight the Blue Button initiative at the DIA 2014 50th Annual Meeting in San Diego. [More]

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941. [More]
Study shows sprifermin reduces cartilage thickness loss in patients with knee osteoarthritis

Study shows sprifermin reduces cartilage thickness loss in patients with knee osteoarthritis

In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. [More]

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Kessler Foundation has been named awardee of a three-year grant for $1.8 million from the Department of Defense Spinal Cord Injury Research Program. Gail Forrest, PT, PhD, is principal investigator for the randomized, double-blinded, controlled, multi-site clinical trial, which will test strategies to improve bone and muscle strength after spinal cord injury. Dr. Forrest is assistant director of Human Performance & Engineering Research at Kessler Foundation. [More]
ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. [More]

Agios begins AG-348 Phase 1 study for treatment of PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers. [More]
Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]
Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML). [More]

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]
Study: HIV-positive women respond well to vaccine against human papillomavirus

Study: HIV-positive women respond well to vaccine against human papillomavirus

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. [More]
Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. [More]

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. [More]
Community efforts boost people for HIV testing and reduce new infections

Community efforts boost people for HIV testing and reduce new infections

Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal The Lancet Global Health. [More]
Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial is published in the journal Stem Cells Research and Therapy, and the approach has been shown to work in two different mouse models. [More]
Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis. [More]

Researchers evaluate rice consumption against overall diet quality and key nutrient intakes

New research, partially funded by the U.S. Department of Agriculture and the USA Rice Federation, shows that consumers can improve their diets simply by enjoying white or brown rice as part of their daily meals. [More]
Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. [More]

Reverse Medical receives FDA IDE approval for BARREL Vascular Reconstruction Device

Reverse Medical Corporation today announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device (VRD). The BARREL Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms. [More]
Study shows how infection worsens damage caused by stroke

Study shows how infection worsens damage caused by stroke

Infection is bad news for all of us - but it can be really serious to people who have had a stroke. Evidence is mounting that infection makes things much worse after a stroke. [More]